Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk

被引:17
作者
Culbert, Kristen M. [1 ]
Thakkar, Katharine N. [1 ,2 ]
Klump, Kelly L. [1 ]
机构
[1] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA
[2] Michigan State Univ, Div Psychiat & Behav Med, Grand Rapids, MI USA
关键词
Estradiol; estrogen; hormones; menopause; menopause transition; midlife; perimenopause; psychosis; schizophrenia; POSTMENOPAUSAL WOMEN; MENSTRUAL-CYCLE; SEX-DIFFERENCES; NATURAL MENOPAUSE; ACOUSTIC STARTLE; STRESS RESPONSES; SYMPTOM SEVERITY; ESTROUS-CYCLE; DAILY-LIFE; SCHIZOPHRENIA;
D O I
10.1017/S0033291722001143
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Women show a heightened risk for psychosis in midlife that is not observed in men. The menopausal transition (i.e. perimenopause) and accompanying changes in ovarian hormones are theorized to account for this midlife increase in risk. This narrative review aims to empirically examine these theories by reviewing studies of midlife and perimenopausal psychosis risk in women and potential ovarian hormone mechanisms of effects. Clinical and pre-clinical studies examining the effects of midlife age, menopausal stage, and ovarian hormones across adulthood on psychosis risk were identified. Synthesis of this body of work revealed that the peak ages of midlife psychosis risk in women overlap with the age range of key menopausal stages (especially the perimenopausal transition), although studies directly assessing menopausal stage are lacking. Studies examining ovarian hormone effects have almost exclusively focused on earlier developmental stages and events (e.g. pregnancy, the menstrual cycle) and show increases in psychotic symptoms in women and female rats during periods of lower estradiol levels. Estrogen treatment also tends to enhance the effects of neuroleptics in females across species at various reproductive phases. Initial data are promising in suggesting a role for menopausal stage and ovarian hormones in psychosis risk. However, critical gaps in our knowledge base remain, as there is a tendency to rely on indirect and proxy measures of menopausal status and hormones. Opportunities for future research are discussed with the goal of increasing research in this critical area of women's health.
引用
收藏
页码:1612 / 1620
页数:9
相关论文
共 94 条
  • [1] Resilience and vulnerability to daily stressors assessed via diary methods
    Almeida, DM
    [J]. CURRENT DIRECTIONS IN PSYCHOLOGICAL SCIENCE, 2005, 14 (02) : 64 - 68
  • [2] American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders: DSM-5, V5th ed., DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
  • [3] Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone
    Arad, Michal
    Weiner, Ina
    [J]. PSYCHOPHARMACOLOGY, 2009, 206 (04) : 731 - 740
  • [4] Fluctuation of latent inhibition along the estrous cycle in the rat: Modeling in the cyclicity of symptoms schizophrenic women?
    Arad, Michal
    Weiner, Ina
    [J]. PSYCHONEUROENDOCRINOLOGY, 2008, 33 (10) : 1401 - 1410
  • [5] Modulation of appetite by gonadal steroid hormones
    Asarian, Lori
    Geary, Nori
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2006, 361 (1471) : 1251 - 1263
  • [6] Hippocampal-prefrontal connectivity as a translational phenotype for schizophrenia
    Baehner, Florian
    Meyer-Lindenberg, Andreas
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (02) : 93 - 106
  • [7] Sex differences in stress responses: a critical role for corticotropin-releasing factor
    Bangasser, Debra A.
    Wiersielis, Kimberly R.
    [J]. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2018, 17 (01): : 5 - 13
  • [8] Sex differences in neural mechanisms mediating reward and addiction
    Becker, Jill B.
    Chartoff, Elena
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (01) : 166 - 183
  • [9] Estrogen augmentation in schizophrenia: A quantitative review of current evidence
    Begemann, Marieke J. H.
    Dekker, Caroline F.
    van Lunenburg, Mari
    Sommer, Iris E.
    [J]. SCHIZOPHRENIA RESEARCH, 2012, 141 (2-3) : 179 - 184
  • [10] Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics
    Bergemann, N
    Mundt, C
    Parzer, P
    Jannakos, I
    Nagl, I
    Salbach, B
    Klinga, K
    Runnebaum, B
    Resch, F
    [J]. SCHIZOPHRENIA RESEARCH, 2005, 73 (2-3) : 357 - 366